Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“The future of multiple myeloma therapy is being shaped right now – and few rising voices are as exciting to follow as Dr. Lekha Mikkilineni from Stanford University School of Medicine.
In the newest episode of MedNews Week Medical Spotlight in partnership with OncoDaily, Dr. Mikkilineni shares insights on:
- The evolving role of CAR T-cell therapy in multiple myeloma
- BCMA and GPRC5D-targeted approaches
- The future of personalized cellular therapy
- Mentorship, innovation, and building a career in academic oncology
A thoughtful conversation with one of the emerging leaders helping define the next generation of hematologic cancer care.”
Quoting OncoDaily‘s post on LinkedIn:
“Excited to share this MedNews Week episode in partnership with OncoDaily featuring Dr. Lekha Mikkilineni from Stanford University School of Medicine.
The discussion explores mentorship, patient-centered care, and the rapidly evolving field of CAR T-cell therapy in Multiple Myeloma, including BCMA and GPRC5D targeted therapies, clinical advances, and the future of personalized oncology.
A fascinating conversation on the future of hematologic cancer treatment.”
Other articles featuring Yan Leyfman on OncoDaily.